FDA Approves Eli Lilly's Foundayo, a Once-Daily Oral GLP-1 Pill for Obesity With No Food or Water Restrictions
The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist from Eli Lilly, for adults with obesity or overweight. It is the first new molecular entity approved under the National Priority Voucher program and the fastest NME approval since 2002.
The U.S. Food and Drug Administration on April 1 approved Foundayo (orforglipron), an oral GLP-1 receptor agonist developed by Eli Lilly, for adults with obesity or overweight accompanied by at least one weight-related medical condition. The approval marks a significant expansion in the obesity treatment landscape, introducing a once-daily pill that can be taken at any time of day without food or water restrictions, a convenience advantage over existing oral GLP-1 options that require empty-stomach dosing.
Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist originally discovered by Chugai Pharmaceutical and licensed by Lilly in 2018. Unlike the peptide-based injectable GLP-1 drugs that have dominated the weight-loss market, orforglipron’s small-molecule structure allows it to survive digestion and be absorbed as a conventional tablet. It is available in six dose strengths ranging from 0.8 mg to 17.2 mg.
Clinical trial results
The approval was supported by the ATTAIN-1 Phase 3 trial, a 72-week, randomized, double-blind, placebo-controlled study that enrolled 3,127 participants across 10 countries. At the highest dose, participants lost an average of 27.3 pounds, or 12.4 percent of body weight, compared with 2.2 pounds (0.9 percent) in the placebo group. Across all doses, the average weight loss was 25 pounds (11.1 percent) versus 5.3 pounds (2.1 percent) with placebo. Secondary endpoints showed reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.
The weight loss achieved by Foundayo falls slightly below the 13.6 percent reported in Phase 3 testing of Novo Nordisk’s oral semaglutide over 64 weeks, according to STAT News. However, the absence of food and water restrictions represents a practical distinction that may influence patient adherence. Novo’s oral semaglutide must be taken on an empty stomach at least 30 minutes before food or beverages other than water.
The labeling for Foundayo includes a boxed warning regarding thyroid C-cell tumors. The drug is contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. Common side effects included nausea, vomiting, and diarrhea, consistent with the GLP-1 drug class. Studies showed no evidence of liver damage despite the small-molecule formulation.
Fastest new molecular entity approval since 2002
Foundayo is the first new molecular entity approved under the FDA’s Commissioner’s National Priority Voucher pilot program, a pathway designed for drugs addressing national health priorities. The approval was issued 50 days after filing, some 294 days before the application’s PDUFA target date of January 20, 2027, making it the fastest NME approval since 2002. The expedited timeline has drawn scrutiny. Critics have described the voucher program as potentially enabling political interference in the regulatory process, though Lilly has emphasized that the FDA conducted a thorough, science-based evaluation.
Pricing and access
Lilly has set Foundayo’s self-pay price at up to $299 per month with continuous prescription renewal, matching the pricing of Novo Nordisk’s oral Wegovy pill, which received FDA approval in December 2025. Patients with commercial insurance may pay as little as $25 per month through a savings card program, and Medicare Part D beneficiaries will be eligible for $50-per-month pricing beginning July 1, 2026. The drug is available immediately through LillyDirect, with prescriptions accepted starting April 1 and shipping beginning April 6, followed by broad availability through U.S. retail pharmacies and telehealth providers.
Competitive landscape
The approval intensifies a commercial contest between Eli Lilly and Novo Nordisk in the oral obesity drug market. Novo secured a head start with its December 2025 approval of oral semaglutide for weight management, which saw rapid adoption. Foundayo’s entry gives physicians and patients a second oral GLP-1 option, one that trades a modest reduction in peak efficacy for simplified dosing logistics.
The broader context is a market where fewer than one in ten eligible patients currently use GLP-1 treatments for weight management. Foundayo is Lilly’s second FDA-approved obesity medication, following its injectable tirzepatide (Zepbound). The Obesity Action Coalition’s Joe Nadglowski stated that new treatment options “expand choice and help more people find care that fits their lives,” underscoring the view among patient advocates that the bottleneck in obesity care has been access and convenience as much as efficacy.